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I About this guide 
This short document aims to provide a summary of the main issues that people engaged 
in developing drug policy, or in commissioning evaluations of drug policy, strategies and 
interventions, need to consider. There are many sources of more detailed information and 
guidance on conducting evaluations. This guide seeks not to duplicate or replace them but 
instead to act as an introduction, providing links to the wider literature and presenting the 
key issues for those managing rather than undertaking drug policy evaluations. Further 
reading and sources of more detailed information are provided at the end of this guide. 
There is also no single correct way to undertake an evaluation, and the choice of approach 
depends on many factors, including timing, objectives and the availability of resources. 
This publication is designed to assist people in choosing the best approach to suit their 
circumstances and to maximise the value of any evaluation.
There is a lot written about evaluation and sometimes the same terms are used to mean 
different things, so before starting it is important to clarify the definitions and concepts that 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) uses in this guide. 
The box below provides the definitions that we use in this guide for certain core concepts. 
Definitions used in this guide
Drug policy is the overall direction and approach taken by a government to address 
(illicit) drug issues. It encompasses the whole system of laws, regulatory measures, 
courses of action and funding priorities concerning (illicit) drugs put into effect by a 
government or its representatives. 
A drug strategy is generally a document, usually time bound, typically containing 
objectives and priorities alongside broad actions, and may identify at a high level the 
parties responsible for implementing them.
An action plan may accompany a drug strategy but is sometimes integrated into that 
strategy. It is typically focused on a relatively short period and identifies more detailed 
actions to implement the strategy, together with timings and responsible parties.
Policy evaluation can be simply defined as an evidence-based judgement about to 
what extent and how well a policy, strategy or intervention has been implemented, and/
or whether the objectives have been achieved, together with any other effects it has 
had. There are a variety of criteria against which such assessments may be made. For 
example, an evaluation may consider whether or not the policy, strategy or intervention 
has:
 ■ been effective (has it achieved its objectives?) and/or efficient (how 
do the resources used relate to the outcomes — positive and/or 
negative)?
 ■ been relevant to both the identified needs and the policy objectives;
 ■ been coherent both internally and in relation to other policy 
interventions; and
 ■ achieved added value — has the existence of the policy/intervention 
improved outcomes over and above what might have been achieved 
anyway?
In addition, an evaluation might consider other criteria such as the quality and extent of 
implementation of the policy (process evaluation), whether or not it is sustainable and 
how fairly its effects are distributed across different stakeholders (equity). Evaluation 
can draw on scientific methods and the collection of empirical and measurable 
evidence to identify causal relationships between actions and outcomes. 
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However, in practice, these terms are often used interchangeably, other definitions may be 
used elsewhere for different purposes and the distinctions between them can be blurred, 
particularly with respect to drug policy and drug strategy. These definitions draw on the 
European Commission’s guidelines and toolkit for evaluation and fitness checks (European 
Commission, 2015a) as well as published and unpublished work undertaken for the 
EMCDDA. Definitions for a wider range of terms can be found in the Glossary (page 22).
I Why evaluate drug policy?
The value of evaluation has been recognised in all EU drug strategies and in the strategies 
of many Member States. The 2013–20 EU Drugs Strategy (Council of the European Union, 
2013) invites EU institutions, bodies and countries to ‘recognise the role of scientific 
evaluation of policies and interventions (with a focus on outcomes achieved) as a key 
element in strengthening of the EU approach to drugs, and [to] promote its use both at 
national, EU and international level’. 
Evaluation is essential for effective policymaking, helping ensure that policies and 
programmes have the desired effect, provide value for money and do not have negative 
unintended consequences. In particular evaluation can contribute to: 
 ■ Better planning of policy and services and the provision of timely and 
relevant advice to support decision-making and input to political priority 
setting. The assessment of the outcomes that have been achieved, and 
for whom, helps ensure that programmes meet the identified needs. 
 ■ Efficient resource allocation — identifying the most effective and 
efficient elements of a policy, or highlighting gaps in provision, can help 
ensure that scarce resources are used to maximum effect.
 ■ Organisational learning — evaluations can not only identify areas for 
improvement but also encourage the sharing of lessons drawn from 
the assessments of both successes and failures. They also provide the 
opportunity to look for ‘unintended’ or ‘unexpected’ effects of actions.
 ■ Transparency and accountability — all stakeholders and the general 
public have a right to know what has been spent on government drug 
policy and what it has achieved. This is important for developing and 
maintaining trust in government and public services.
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* There is no one ‘correct’ way to perform an evaluation of drug policy. 
What is best will depend on what you want to know, what data you have 
available or can obtain, and the resources and time available to you.
* Evaluation should not be seen as a one-off event but will be most useful 
if viewed as an ongoing process intertwined with policy or strategy 
development and implementation.
* Evaluation needs to be accompanied by a commitment to taking action 
on the findings, and the opportunity to do so. The timing and choice 
of evaluation design need to be realistic and take this into account; 
producing a detailed evaluation of a previous strategy only after a new 
strategy has been developed and implementation begun will limit its 
usefulness.
* Developing the expertise and data sources for drug policy evaluation 
over time will increase the ability to conduct evaluations in support of 
drug policy development and enhance action to address drug problems.
I  Key  messages
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Preparing the  
ground1
There are number of key factors that facilitate successful evaluation and which it is 
important to establish at the outset:
 ■ Leadership commitment to the process
This is essential for a successful evaluation. Ownership of the process by senior 
government officials and politicians is key to obtaining sufficient resources; without it, 
it will be difficult to ensure that the findings of the evaluation are acted upon. Where a 
culture of evaluation exists, leadership support is likely to be easier to achieve. 
 ■ Adequate resources — finances and skills
A comprehensive and thorough evaluation of drug policy requires considerable skills 
and time, and hence is costly. When designing the evaluation it is important to be 
realistic about how much can be achieved within the resources available. A narrower, 
focused evaluation, which will be properly carried out, can be more useful than a more 
ambitious but under-resourced, and hence poorly performed, exercise.
 ■ Stakeholder engagement
The involvement of stakeholders in an evaluation contributes to its development, 
quality and transparency. Stakeholders’ involvement can facilitate access to relevant 
data and individuals, and ensure that the approach taken is realistic, covers the most 
important aspects of the policy or strategy, and represents all relevant geographical 
areas and affected groups.
 ■ Establishing a steering group
It is considered good practice to establish a steering group to guide the evaluation 
process. To achieve the benefits described above, it is important to include 
representation from the following stakeholders: 
 » policymakers (e.g. national drug policy coordinators, representatives of relevant 
ministries such as those of health and justice);
 » public officials (e.g. local drug coordinators, national focal points, administration, 
government agencies);
 » target groups and beneficiaries (e.g. health professionals, police forces, social 
workers, service user groups);
 » experts in drug policy and evaluation methodology (e.g. consultants, academics); 
civil society groups.
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Deciding on the  
type and scope of  
the evaluation2
Evaluation is often seen as something that takes place at the end of a strategy or action 
plan period. However, ideally evaluation is an ongoing process, intertwined with the policy 
cycle, and with different types of evaluation providing different types of information at 
different times. There is also no single ‘correct’ type or model of evaluation that will answer 
all questions or suit all circumstances. There are therefore a number of questions to be 
considered when deciding on the type and scope of evaluation that suits the circumstances 
in any particularly case:
 ■ To evaluate the overall policy/strategy, or individual programmes/elements?
Although occasionally the overall drug policy may be evaluated, the two main 
options are generally an overarching evaluation of the national drug strategy (general 
evaluation) and the evaluation of a number of key interventions (targeted evaluation). 
Factors that may influence the choice of what to evaluate include the purpose of 
the evaluation, the stage of the policy cycle at which it is being conducted and the 
resources available. For example:
 » A general evaluation will be the preferred option when, as is often the case, the 
aim of the evaluation is to improve the quality, efficacy and efficiency of the drug 
strategy as a whole. This broad type of evaluation can also provide the opportunity 
to compare the effectiveness of a strategy’s various elements, the interactions 
between them and the relative priority given to them during implementation.
 » A targeted evaluation should be carried out when more in-depth assessment of 
one or a limited number of key interventions is needed. Narrowing the scope of the 
evaluation allows more detailed investigation of a particular intervention, and is 
often used when a new intervention approach is being developed or rolled out.
However, it is important to note that these types of evaluation are not mutually 
exclusive. Different approaches may be used at different stages in the evaluation and 
the policy cycle, and a ‘mixed approach’ can also be adopted, for example assessing 
the implementation of all elements of a strategy while focusing on the effectiveness 
and efficiency of some key components.
 ■ At what stage(s) of the policy cycle will the evaluation be conducted?
The policy process can be viewed as cyclical: starting with the formulation of a 
policy, it continues through planning and resource allocation, programme design, 
implementation and the delivery of outputs and results. Evaluation follows a similar 
cyclical process and can be addressed through ex ante (before), interim or ex nunc 
(during) and ex post (after) evaluations. The policy and evaluation processes, therefore, 
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Step 2 I Deciding on the type and scope of the evaluation
should be seen as parallel 
cycles influencing one 
another (Figure 1). 
The differing types of 
evaluation provide a variety 
of information appropriate 
to the different stages of 
the policy cycle (see box on 
page 9), although the 
division between them is not 
absolute and, in practice, 
various combinations of these 
approaches can be used at 
different points in a strategy’s 
life cycle. For example, an ex 
post evaluation at the end of 
one strategy time period may 
also act as, or form part of, an 
ex ante evaluation of a new 
strategy.
 ■ Feasibility considerations — resources, time, data
The ideal evaluation is established right from the outset of a policy or programme, 
with data collection built in from the start and with sufficient resources and time set 
aside for detailed analysis by skilled professionals. However, a common criticism of 
evaluations of drug policy is that, as a result of data limitations, timeliness issues 
or under-resourcing, they can struggle to deliver useful results. It is important to 
be realistic in designing your evaluation and, if necessary, to design a more limited 
evaluation focused on key issues for the next policy phase rather than aim for a more 
extensive evaluation that is unachievable (evaluation design is discussed in more 
detail in steps 4 and 5).
Policy 
review
Policy 
formulation
Programme 
conclusions
Programme 
design
Ex ante
feasibility
evaluation
Ex post/
results
evaluation
Ongoing/
mid-term
evaluation
Programme 
implementation
Policy 
delivery
FIGURE 1
Parallel cycles
Source: European Commission, 2013.
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Main types of evaluation and their different uses
There are a number of different, and to some extent overlapping, ways of categorising policy and strategy 
evaluations, as illustrated by the examples in the table below. One can identify them firstly by the stage of 
the policy process in which they take place, secondly by the type of evaluation and thirdly by the criterion 
against which the judgement is to be made. A further dimension that could be considered is the tool or 
method to be used in the assessment. The list given here is not exhaustive but illustrates the range of 
alternatives, including both data sources and analytical approaches.
When Type of evaluation Criteria assessed Methods/tools
Ex ante evaluations
Interim or ex nunc 
evaluations
Final or ex post 
evaluations
Formative evaluations
Summative evaluations
Policy appraisals
Impact assessments
Process evaluations
Outcome/effectiveness evaluations
Impact evaluations
Economic evaluations
Relevance
Coherence
Effectiveness
Efficiency
Added value
Equity
Sustainability
Documentary analysis
Focus groups/interviews
Surveys
Administrative data
Public expenditure studies
Social cost studies
Cost-effectiveness analysis
Cost–benefit analysis
Statistical modelling
How these different aspects may be linked together within the overall evaluation approach is illustrated below:
(i) Ex ante evaluations
Policy appraisals and impact assessments are types of ex ante evaluation and are carried out as part of 
the policy development process. They focus on policy content, assessing criteria such as relevance and 
coherence, but may also consider what the expected costs and impact will be, based on previous research or 
evaluation evidence, and make comparisons with alternative policy options. The purpose is to make sure that 
the policy is realistic, affordable and likely to achieve the desired outcomes before it is fully implemented, in 
order to maximise the likelihood that it will succeed.
(ii) Interim (or ex nunc) evaluations 
These take place part way through the policy or programme cycle with the aim of making improvements, and 
are often used for mid-term drug strategy evaluations, for instance after the end of a first action plan. These 
are usually formative or process evaluations that look mainly at the extent to which the policy or activity has 
been implemented and if this was done as intended. However, they can also include some consideration of 
outputs, outcomes and the extent to which different target groups have been reached, i.e. effectiveness and 
equity issues. These types of evaluation are particularly important for new programmes that may not work 
or may need adjustment when rolled out, as well as for longer-term strategies that may need to adjust to 
changes in patterns of drug use or the wider social or economic environment. 
(iii) Final or (ex post) evaluations
Outcome and impact evaluations are common components of ex post evaluations (i.e. evaluations conducted 
at the end of a programme or strategy). These are types of summative evaluation, which look at the extent to 
which a policy or programme has met its goals and had any other consequences, and draw lessons based on 
these assessments. The main focus at this stage is often on effectiveness, added value and efficiency, that 
is whether or not the objectives of the policy or programme were achieved and represented a good use of 
resources. Nevertheless, in addition they usually seek to identify other lessons for future policy development, 
such as issues that have acted as barriers and key factors for success, so they often also include process 
evaluations or implementation reviews. 
Economic evaluations may form a part of evaluations conducted at any stage of the policy process. They 
are often used to assess the efficiency of the programme and/or compare alternative courses of action, 
relating the resources used to what is achieved in terms of outputs and the programme objectives. There are 
a number of different tools and analytical approaches that can be used in economic evaluations, including 
cost-effectiveness and cost–benefit analyses. Public expenditure and social-cost studies are often important 
components of economic evaluations of drug policy and strategies
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An evaluation may be conducted by an internal or external team, or a combination of the 
two. Whether an evaluation should be considered internal or external is also not necessarily 
clear-cut. In some cases the government may have a central department or unit with the 
remit to conduct policy evaluations or reviews, and while internal to the government it will 
be external to the departments responsible for drug policy. Similarly, external evaluation 
teams may be from organisations external to the government but from within the country 
concerned, e.g. academic institutions or evaluation professionals, or come from outside the 
country.
In choosing what is most appropriate for a particular situation there are a number of factors 
to consider:
 ■ The importance of independent evaluation
If an evaluation is to provide findings that are considered trustworthy, it is important 
that it is objective and independent. People who have been closely involved in 
implementing a strategy may find it difficult to be unbiased when judging the success 
of the different elements of the work, or may come under pressure to downplay 
problems. External evaluators may be less susceptible to these influences, but on the 
other hand may be more vulnerable to ‘capture’ by more vocal stakeholder groups 
and lack important contextual knowledge. Such a lack may have a negative impact 
on resources and timing, because of the need to bring the evaluators up to speed, 
and on the usefulness of their recommendations. Even when internal evaluators are 
objective, they may not be perceived as such, so in circumstances where the policy is 
contentious it may be considered preferable to have an external team.
 ■ The need for expertise and knowledge in both evaluation and drug policy
Expertise in evaluation is clearly important for both the design and conduct of the 
evaluation, but knowledge of drug policy issues is also necessary to ensure that the 
research questions and indicators used to assess outcomes are appropriate, and to 
guide the analysis and ensure useful conclusions and recommendations. Evaluators 
from another country or from international agencies will often have only limited 
knowledge of national drug policy issues so they are likely to need support and 
guidance about them. 
 ■ The available resources and the time allowed for the evaluation
Both internal and external evaluations require adequate resourcing. If the time 
allocated for the evaluation is very limited then it may be difficult to contract an 
external team within the time frame.
Choosing an 
evaluation team3
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Step 3 I Choosing an evaluation team
These factors will need to be weighed against each other and the relative importance of 
each will vary depending on circumstances. For example, as discussed above, internal 
evaluation teams may be seen as biased and have limited evaluation expertise, but they 
know the drug policy context intimately, understand the data sources available and may 
be aware of occurrences that have not been documented. Similarly, external teams may 
be more trusted by the stakeholders, who in turn may be more honest with them, and 
they may find it easier to be objective and to deliver ‘uncomfortable’ lessons, but on the 
other hand they may need a lot of support in understanding local circumstances and data 
sources. Language issues may also be an important consideration; clearly, teams from 
within the country will speak the national language and thus be able to read the necessary 
documents and conduct interviews with all stakeholders, which may be a problem for 
some external evaluators.
In practice, some sort of joint evaluation team or approach may be the best solution. In 
these circumstances, the roles and responsibilities of internal and external team members 
will need to be clearly defined from the outset. However, in all cases it will be important 
to have clear terms of reference for the evaluation, as well as more detailed plans that are 
reviewed regularly.
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Evaluation design: 
research questions 
and methods4
In considering which methodology to adopt for the evaluation, a number of different factors 
need to be addressed:
 ■ First establish the research questions, i.e. what it is that you want to learn 
from the evaluation. 
For example, do you want to know if all the actions envisaged have been undertaken; 
whether or not the expected outcomes have been achieved; or if one component of 
the strategy was more effective than another? The evaluation questions need to be 
appropriate to the stage in the policy cycle and the goal of the evaluation (e.g. is it an 
interim evaluation aimed at improving the implementation of a strategy or a particular 
intervention; is it being conducted to identify the impact that has been achieved?). In 
outcome or impact evaluations, these questions will obviously need to be linked to the 
objectives of the policy or programme being evaluated. It is common to have several 
different research questions for an evaluation, relating to different evaluation criteria, 
but too many or too complex questions may overburden the evaluation and cause it 
to lose focus. The questions also need to be specific, measurable, achievable, relevant 
and time bound (SMART):
 » specific — they must clearly stipulate what is to be evaluated (e.g. a strategy, part 
of a strategy, an intervention);
 » measurable — the questions must be translatable into measurable criteria;
 » achievable — it is important to be realistic about what can be achieved with the 
resources, time and data available;
 » relevant — questions must meet the concrete needs of policymakers/stakeholders 
and provide useful and useable information;
 » time bound — the time period to be covered needs to be made clear.
Examples of types of research questions addressing different criteria and relating to 
different types of evaluation are given in the box on page 13.
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Step 4 I Evaluation design: research questions and methods
 ■ Then choose the appropriate evaluation approach to address the 
research questions.
Choice of evaluation method is likely to be an iterative process involving the evaluation 
team. If external consultants are involved, they may be requested to propose a 
methodology for answering the research questions in their proposal. There are a range 
of methods and tools that can be used to answer different types of question, and some 
provide more robust evidence than others. In outcome and impact evaluations, linking 
interventions causally with outcomes is a common goal, and some evaluation designs 
are better than others at demonstrating causal linkages (see the box on page 14). 
However, while experimental designs such as randomised controlled trials may be 
appropriate for evaluating individual interventions, these are not usually feasible when 
broader drug strategies are being considered, and drawing firm conclusions on cause 
and effect is extremely difficult. In such cases, alternative evaluative approaches that 
focus more on how and why interventions are working, and contextual factors that may 
affect outcomes, such as ‘realist evaluation’ approaches, may be more useful (Pawson 
and Tilley, 2004). 
Although the robustness of the findings from a particular evaluation method is a very 
important consideration, the choice will also depend on other factors such as data 
availability and quality, and time and resources available. A less ambitious but more 
focused and clearly targeted analysis that is achievable in the available time frame is 
likely to be more valuable than a more complex but under-resourced evaluation that 
fails to deliver or provides findings too late to be useful.
There are many and varied tools and techniques for data collection and analysis 
that may be used in an evaluation. These include document reviews (e.g. of policy 
documents, budget reports, meeting records or research publications), case studies, 
participatory observation, interviews, focus groups, questionnaire surveys, panels of 
experts, spatial analysis, multi-criteria analysis and modelling. The selection of tools 
will depend on the type of data required, data availability, the research question to be 
answered, the availability of the necessary skills and resources, and other practical 
considerations.
Examples of some types of research question
Considering relevance: ‘To what extent were the goals and interventions identified 
in the 200X–201X drug strategy relevant to the drug problems being experienced 
at the beginning and end of the time period it covered?’ 
For a process evaluation looking at implementation: ‘Was the drug intervention 
designed and managed in a way that ensured that it was implemented efficiently 
and according to the timetable set out at the start?’; or ‘To what extent were the 
different actions planned under the 200X–201X drug strategy implemented, and 
what factors acted as barriers or facilitators to implementation?’
For an outcome evaluation: ‘To what extent does the drug intervention, as it is 
now configured, satisfy the needs of its beneficiaries with regard to health and 
treatment?’
Relating to impact: ‘To what extent did the 200X–201X drug strategy lead to a 
decrease in drug supply?’
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Rating the strength of an outcome evaluation — the Maryland Scientific 
Methods Scale
For evaluations that seek to assess outcomes and impact, and to attribute these to a 
particular policy or intervention (causal inference), a common way of rating the strength 
of the evaluation design is the Maryland Scientific Methods Scale (Farrington et al., 
2002). This was originally developed for reviewing evidence in the crime prevention field, 
and it grades evaluation designs from level 1, the lowest, to level 5, which provide the 
strongest evidence that the outcome seen was a result of the intervention. 
The most common type of outcome evaluation is one that occurs after implementation, 
and involves comparing measures relating to the implementation of the intervention with 
measures of its supposed effects (e.g. on drug supply or use), and assessing the extent 
to which these are correlated. This is a level 1 type of evaluation. Like level 2 evaluations, 
which use data collected both before and after the intervention but with no control 
groups, it shows only association and not causation. 
Levels 3 to 5 (randomised controlled trials) involve experimental designs that compare 
groups or areas that have received the intervention with similar groups or areas that 
have not. They provide evidence of causation but need to be integral to the intervention 
process and are really suited only to evaluation of specific interventions, such as a new 
treatment programme.
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Evaluation design: 
logic models or  
cause-and-effect 
chains and data 
requirements5
To decide what to measure to answer the research questions chosen, it is important to 
understand the components of the policy/strategy/intervention under consideration, and 
how it was expected to achieve its aims. This is also important for refining the research 
questions and making them SMART. 
The following elements of the strategy or intervention to be evaluated need to be identified 
(W. K. Kellogg Foundation, 2004; OECD, 2010):
 ■ the needs and problems that the intervention aims to solve; 
 ■ the activities which are a part of the intervention — actions to achieve 
the aims of the intervention;
 ■ the financial and material inputs, and the organisational and regulatory 
inputs (including human resources, budgets and equipment), that 
make it possible to implement the intervention and deliver the intended 
results;
 ■ the intended products or outputs of the intervention, such as the 
number of activities undertaken related to the aim of the intervention 
(e.g. numbers treated, drug seizures and training packages developed);
 ■ the intended changes in behaviour and knowledge, or outcomes — the 
short- and medium-term results and consequences of the intervention 
which are related to its aim;
 ■ the wider changes or impacts, such as health improvements or reduced 
crime, which are the long-term consequences of the intervention, direct 
and indirect as well as intended and unintended.
Taken together, these different components describe the logic model or cause-and-effect 
chains that underpin the strategy or intervention. In an ideal world, these would be clearly 
spelled out in the strategy or project documents. The more links in the objective-activities-
output-outcome-impact chain that are clearly identified from the outset, where possible 
alongside proposals for monitoring them, the more amenable to evaluation the strategy 
will be. However, in the real world it is often necessary to construct them based on a 
review of a variety of documents, which in the case of drug strategies might include the 
EU’s strategy and action plans; laws, decrees or other legal acts; documents supporting 
the planning, budgeting and management of the intervention; monitoring data; reports of 
audits; reviews; and previous evaluations. If the necessary information is lacking in official 
documents, additional key informants could be interviewed.
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Some examples of such models are shown in Figure 2, to clarify the terminology and 
underlying principles (Emmanuelli and Desenclos, 2005). In practice, there will often be a 
range of activities under each objective, several different outputs from an activity, and so 
on. In these cases a number of different models or a branching model may be appropriate.
These logic models and the research questions to which they relate help to identify the sort 
of information, or indicators, that will need to be collected to conduct the evaluation. These 
indicators include measures of inputs, outputs, outcomes and impact. Process evaluations 
will tend to focus mainly on describing the activities undertaken, the inputs and outputs, 
and contextual factors such as barriers and facilitators to implementation. Outcome and 
impact assessments will need information about the activities conducted, as well as 
measures of what has been achieved, in order to link one to the other as far as is possible.
The indicators used in evaluation could be existing datasets which are already monitored 
regularly. Such indicators can, for example, be found in routine government statistical 
publications or at monitoring centres. The epidemiological, supply-side and other 
indicators available in the many publications of the EMCDDA and its Reitox national 
focal points can be used in evaluation studies. These indicators cover both supply- and 
demand-side activities and include potential input, output, outcome and impact measures. 
Examples are: 
 ■ public expenditure (input);
 ■ number of needle and syringe exchange programmes (input);
 ■ number of drug-related research projects funded (output);
 ■ number and quantity of illicit drug seizures (output);
 ■ drug users entering treatment services (output);
 ■ number of drug law offences (output);
FIGURE 2
Examples of cause and eect chains
OBJECTIVE
Reduce health 
and social risks 
and harms 
associated with 
injecting drug 
use   
 
ACTIVITIES
Free sterile 
syringes 
provided to drug 
users  
OUTPUT
Number of free 
sterile syringes 
provided to drug 
users    
OUTCOME
Prevention of 
syringe sharing 
IMPACT
Decrease in 
transmission 
of HIV and 
hepatitis C 
virus  
 
OBJECTIVE
Reduce health 
and social risks 
and harms 
associated with 
opioid use
 
 
 
ACTIVITIES
Substitution 
treatment for 
opioid users  
OUTPUT
Number of 
prescriptions of 
buprenorphine 
and methadone
 
OUTCOME
Reduced 
injecting 
Reduced illicit 
opioid use 
IMPACT
Decrease in 
opioid-related 
deaths   
OBJECTIVES
Prevent drug 
use and delay 
the age of rst 
use of illicit 
drugs
 
ACTIVITIES
Drug prevention 
training for 
teachers
 
 
OUTPUT
Number of 
teachers trained  
OUTCOME
Teachers 
implement 
programme in 
schools
 
IMPACT
Drug use at 
young age 
decreases
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 ■ drug-related crime (output/impact);
 ■ prevalence of drug use in specific populations (e.g. prisons)  
(outcome/impact);
 ■ prevalence of drug use among the general population (impact);
 ■ incidence of drug use (impact);
 ■ age of initiation of drug use (impact);
 ■ problem drug use (impact);
 ■ drug-related infectious diseases (impact);
 ■ drug-related deaths (impact);
 ■ purity of drugs (impact);
 ■ prices of drugs (impact);
 ■ market size estimates (impact).
It is also possible to use ad hoc indicators. Especially for the evaluation of specific 
interventions, these indicators are likely to be necessary. However, unless introduced 
at the beginning of the programme, pre-existing baseline data may not be available for 
comparison, limiting the strength of the evaluation. Special data collections may also take 
time and delay the evaluation, so planning these in advance is needed to avoid delays. 
Examples of such indicators are: 
 ■ cost of harm-reduction programmes (input);
 ■ number of sterile syringes sold and distributed (output);
 ■ drug-related arrests (output);
 ■ rate of syringe sharing among injecting drug users (outcome).
Specific data collection is also likely to be essential to obtain information on the activities 
undertaken and contextual factors that have a bearing on the implementation and 
outcomes achieved. In this context, interviews or focus groups with representatives of key 
stakeholder groups, documentary analysis and questionnaire surveys are all likely to play 
a role.
The research questions, the type of evaluation, the indicators and the tools used to obtain 
them all need to be linked, as shown in the following example:
An outcome evaluation: ‘To what extent does the drug intervention satisfy the needs of its 
beneficiaries with regard to health and treatment?’ 
CRITERION: Effectiveness
TOOL: Questionnaire survey
INDICATORS: Rate of satisfaction with quality and effectiveness of 
treatment services, from ‘very dissatisfied’ (1) to ‘very satisfied’ (5), with 
regard to waiting time, availability of staff, usefulness of information, 
outcomes of treatment, accessibility of infrastructure, equipment, etc.
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Even if the evaluation is being undertaken by external evaluators, those with responsibility 
for the evaluation will need to be involved beyond the design phase and throughout the 
evaluation process, in a range of ways including:
 ■ Facilitating access to stakeholders and data sources
While some of the routine statistical information may be readily available on the 
internet, much of the information about activities such as expenditure and throughput 
will need to be obtained for the evaluators. For external evaluators, assistance in 
translating data sources may sometimes be necessary. In addition, identifying potential 
stakeholders for interviews or surveys and obtaining their consent or, if appropriate, 
agreeing mechanisms for reaching them that maintain confidentiality is also likely to be 
necessary.
 ■ Monitoring progress
This is important to ensure that the evaluation remains on track and to deal with any 
practical difficulties — including access to key individuals and problems obtaining 
data — that may be encountered. Senior government officials and politicians with 
responsibility for the drug policy area, and other stakeholders, need to be kept informed 
of progress to ensure they remain engaged in the process. Establishing reporting 
mechanisms within the project plan for the evaluation, e.g. requirements for inception 
and interim reports, will facilitate this. If a steering committee has been set up to 
oversee the evaluation, this will be an important task for it.
 ■ Providing input or a reality check to recommendations, if appropriate
Although an evaluation needs to be objective and benefits from independence, it can 
be useful to discuss any recommendations being considered, to ensure that they 
are appropriate to the legal and administrative frameworks of the country involved. 
This may take place through comments on draft recommendations, or the evaluators 
may wish to engage the steering groups or stakeholder focus groups in developing 
recommendations based on the conclusions of the evaluation. This may facilitate 
the adoption of the recommendations and ensure they can be acted on. To avoid 
perceptions of undue influence on the findings and associated loss of independence, 
it might be useful to separate the initial evaluation, containing the judgement of the 
successes and failures of the strategy or intervention, from the process of developing 
recommendations for action. The evaluation findings could be presented as a separate 
report, or as one section of an overall report, to be followed by a separate section 
on ‘taking the actions forward’, setting the findings in the operating context of any 
upcoming strategy. This allows a mechanism for both the evaluators and those who 
must implement the results to contribute.
During the  
evaluation
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I Taking action and making changes
It is unlikely that any evaluation will conclude that the intervention or strategy is perfect, not 
least because the context in which the programme is operating is likely to have changed 
over time. The benefits from evaluation are obtained only when changes are made that 
improve the operation and outcomes of the intervention or strategy in question, or such 
changes are incorporated into subsequent interventions and strategies. Therefore, it is 
important to consider the timing and mechanisms for disseminating and implementing the 
recommendations of the evaluation right from the start. This might include taking account 
of the likely timeline for development of the next strategy when designing the evaluation of 
the current one, to ensure sufficient time for the evaluation findings to be used within the 
new strategy development process. Another example is that it might be important for the 
evaluation’s budget to include costings for the dissemination of the evaluation findings to 
local governments and agencies. 
I Drawing lessons for the next evaluation
In the guidance above we have stressed the need to be pragmatic and to recognise that 
it may not be possible to undertake an ‘ideal’ evaluation of the highest quality, i.e. built 
in from the start, including interim evaluations and a full impact assessment that clearly 
demonstrates causation and assesses cost–benefit or cost-effectiveness. Evaluating a 
complex policy area such as the illicit drugs field is a very difficult undertaking and the 
hidden nature of drug use and supply makes it difficult to obtain accurate measures of 
many of the outcomes targeted. Nevertheless, performing the best evaluation possible 
under the circumstances can provide valuable information and is also likely to highlight 
the key data gaps and areas where improvements can be made. This can encourage the 
incorporation of evaluation from the beginning of the policy cycle and the allocation of 
resources to improving data sources.
I Developing an evaluative culture
Over time this should lead to the development of an evaluative culture (OECD, 2016) and 
an improvement in the information and resources available for drug policy evaluation. 
Particular areas where quality improvements will support better evaluations include 
data collection systems, clearer logic models underpinning strategies and enhanced 
coordination. In turn, improved evaluations should contribute to more effective and efficient 
interventions.
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I   Sources and  further reading
Below can be found details of the documents referenced in the seven-step guide, as well 
as some other materials that may be useful to people involved in evaluations in the field of 
drug policy.
I  Council of the European Union (2013), European Union Drugs Strategy 2013–2020, 
Publications Office of the European Union, Luxembourg (available at: http://dx.publications.
europa.eu/10.2860/69835).
I  Evaluation guides and texts
I  European Commission (2013), EVALSED: The resource for the evaluation of socio-
economic development, European Commission, Brussels. 
I  European Commission (2015a), Better regulation toolbox (http://ec.europa.eu/smart-
regulation/guidelines/docs/br_toolbox_en.pdf). 
I  European Commission (2015b), Better regulation guidelines, SWD(2015) 111 final (http://
ec.europa.eu/smart-regulation/guidelines/docs/swd_br_guidelines_en.pdf).
I  Farrington, D. P., Gottfredson, D. C., Sherman, L. W. and Welsh, B. C. (2002), ‘Maryland 
Scientific Methods Scale’, in Sherman, L. W., Farrington, D. P. et al (editors) Evidence-based 
crime prevention, pp. 13–21, Routledge, London.
I  Fretheim, A., Oxman, A. D., Lavis, J. N. and Lewin, S. (2009), ‘Support tools for evidence-
informed policymaking in health 18: Planning monitoring and evaluation of policies’, Health 
Research Policy and Systems 7, pp. 1–8.
I  OECD (Organisation for Economic Co-operation and Development) (2010), Quality standards 
for development evaluation, OECD, Paris (available at: http://www.oecd-ilibrary.org/
development/dac-quality-standards-for-development-evaluation_9789264083905-en). 
I  OECD (2016), Evaluation systems in development co-operation: 2016 review, OECD, Paris 
(http://www.keepeek.com/Digital-Asset-Management/oecd/development/evaluation-
systems-in-development-co-operation_9789264262065-en).
I  Pawson, R. and Tilley, N. (2004), Realist evaluation (http://www.communitymatters.com.
au/RE_chapter.pdf).
I  W. K. Kellogg Foundation (2004), Logic model development guide, W. K. Kellogg Foundation, 
Battle Creek.
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I  Published examples of drug strategy evaluations
I  Emmanuelli, J. and Desenclos, J.-C. (2005), ‘Harm reduction interventions, behaviours and 
associated health outcomes in France, 1996’, Addiction 100(11), pp. 1690–1700.
I  Galla, M., Van Gageldonk, A., Trautmann, F. and Verbraeck, H. (2006), Evaluation of the 
implementation of the national strategy to combat drugs: A Hungarian-Dutch cooperation. 
Report of the external mid-term evaluation, Trimbos Institute, Utrecht.
I  Griffiths, P., Strang, J. and Singleton, N. (2016), Report of the rapid expert review of the 
national drugs strategy 2009–2016 (http://health.gov.ie/wp-content/uploads/2016/09/
Rapid-Expert-Review-of-the-National-Drugs-Strategy-2009-2016.pdf).
I  Portuguese National Institute of Public Administration (PNIPA) (2004), External and 
independent evaluation of the national strategy for the fight against drugs and the national 
action for the fight against drugs and drug addiction, Horizon 2004, PNIPA, Lisbon.
I  Data sources for evaluation
I  EMCDDA Statistical Bulletin (available at: http://www.emcdda.europa.eu/data/stats2016).
22 / 27
I  Glossary of key terms  used in evaluations
Activities — processes, tools, events, technology and actions that are part of the 
programme implementation. These interventions are used to bring about the intended 
programme changes or results, i.e. the actions taken or work performed to achieve the aims 
of the intervention.
Added value — the extent to which something happens as a result of an intervention or 
programme that would not have occurred in the absence of that intervention. Also known as 
‘additionality’. 
Aim — the purpose of, for example, an intervention or a policy.
Causality — an association between two characteristics that can be demonstrated to be 
due to cause and effect, i.e. a change in one causes the change in the other.
Coherence — the extent to which intervention logic is non-contradictory or the extent to 
which the intervention does not contradict other interventions with similar objectives.
Control group — a group of participants in a study not receiving a particular intervention, 
used as a comparator to evaluate the effects of the intervention.
Criterion — character, property or consequence of a public intervention on the basis of 
which a judgement will be formulated.
Data — information; facts that can be collected and analysed in order to gain knowledge or 
make decisions. 
Drug action plan — scheme or programme for detailed specific actions. It may accompany 
or be integrated into a drug strategy but typically focuses on a relatively short period 
and identifies more detailed actions to implement the strategy, along with timings and 
responsible parties.
Drug policy — overall philosophy on the matter; position of the government, values 
and principles; attitude, direction. It encompasses the whole system of laws, regulatory 
measures, courses of action and funding priorities concerning (illicit) drugs put into effect 
by governments.
Drug strategy — unifying theme; framework for determination, coherence and direction. It 
is generally a document, usually time bound, containing objectives and priorities alongside 
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broad actions, and may identify, at a top level, the parties responsible for implementing 
them.
Effectiveness — the fact that expected effects have been obtained and that objectives have 
been achieved.
Efficiency — the extent to which the desired effects are achieved at a reasonable cost.
Equity — the extent to which different effects (both positive and negative) are distributed 
fairly between different groups and/or geographical areas. 
Evaluation — a periodic assessment of a programme or project’s relevance, performance, 
efficiency and impact in relation to overall aims and stated objectives. It is a systematic tool 
which provides a rigorous evidence base to inform decision-making. 
Evaluation criteria — aspects of the intervention which will be subject to evaluation. Criteria 
should fit the evaluation question. If all the criteria are put together, they should account for 
a good and complete measurement. Examples are relevance, efficiency and effectiveness.
Evaluation question — question asked by the steering group in the terms of reference and 
which the evaluation team will have to answer.
Evaluation team — the people who perform the evaluation. An evaluation team selects and 
interprets secondary data, collects primary data, carries out analyses and produces the 
evaluation report. An evaluation team may be internal or external.
Evidence-based — conscientiously using current best evidence in making decisions.
Evidence-informed policy — an approach to policy decisions that aims to ensure that 
decision-making is well informed by the best available research evidence.
Ex ante evaluation — an evaluation that is performed before implementation of an 
intervention. This form of evaluation helps to ensure that an intervention is as relevant 
and coherent as possible. Its conclusions are meant to be integrated when decisions are 
made. It provides the relevant authorities with a prior assessment of whether or not issues 
have been diagnosed correctly, whether or not the strategy and objectives proposed are 
relevant, whether or not there is incoherence between them or in relation to other related 
policies and guidelines, and whether or not the expected impacts are realistic.
Ex nunc (or interim) evaluation — an evaluation that is performed during implementation.
Ex post (or final) evaluation — evaluation of an intervention after it has been completed. It 
strives to understand the factors of success or failure.
External evaluation — evaluation of a public intervention by people not belonging to the 
administration responsible for its implementation.
Feasibility — the extent to which valid, reliable and consistent data are available for 
collection.
Impact — fundamental intended or unintended change and direct or indirect 
consequences occurring in organisations, communities or systems as a result of 
programme activities within 7 to 10 years, i.e. long-term consequences of the intervention.
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Impact (or outcome) evaluation — evaluates whether the observed changes in outcomes 
(or impacts) can be attributed to a particular policy or intervention, i.e. determining 
whether or not a causal relationship exists between an intervention or policy and changes 
in the outcomes.
Indicator — quantitative or qualitative factor or variable that provides a simple and reliable 
means to measure achievement, to help assess the performance of a policy/intervention 
(to reflect the changes connected to an intervention, an output accomplished, an effect 
obtained or a context variable — economic, social or environmental).
Input — financial, human, material, organisational and regulatory means mobilised for the 
implementation of an intervention.
Internal evaluation — evaluation of a public intervention by an evaluation team belonging to 
the administration responsible for the programme.
Joint evaluation — evaluation of a public intervention by an evaluation team composed of 
both internal (people belonging to the administration responsible for the programme) and 
external evaluators.
Maryland Scientific Methods Scale — a system that provides an overview of evaluation 
designs.
Method — complete plan of an evaluation team’s work. A method is an ad hoc procedure, 
specially constructed in a given context to answer one or more evaluative questions. Some 
evaluation methods are of low technical complexity, while others include the use of several 
tools.
Monitoring — a continuing function that uses systematic collection of data on specified 
indicators to provide management and the main stakeholders of an ongoing intervention 
with indications of the extent of progress, achievement of objectives and progress in the 
use of allocated funds.
Need — problem or difficulty affecting concerned groups, which the public intervention 
aims to solve or overcome.
Norm — level that the intervention has to reach to be judged successful, in terms of a 
given criterion. For example, the cost per job created was satisfactory compared with a 
national norm based on a sample of comparable interventions.
Outcomes — the likely or achieved short- and medium-term effects of an intervention’s 
outputs, relating to the aim of the intervention. Specific changes in programme 
participants’ behaviour, knowledge, skills, status and level of functioning.
Outputs — direct products of programme activities which may include types, levels and 
targets of services to be delivered by the programme.
Process evaluation — one that focuses on programme implementation and operation. A 
process evaluation could address programme operation and performance.
Programme logic model — picture of how a policy/intervention works — the theory 
and assumptions underlying the programme. A programme logic model links outcomes 
(both short- and long-term) with programme activities/processes and the theoretical 
assumptions/principles of the programme.
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Public managers — public (sometimes private) organisations responsible for 
implementing an intervention.
Random assignment — making a comparison group as similar as possible to the 
intervention group, to rule out external influences; randomly allocating individuals to either 
the intervention group or the control group.
Randomised controlled trial (RCT) — an experiment in which two or more interventions, 
possibly including a control intervention or no intervention, are compared by being 
randomly allocated to participants.
Relevance — the extent to which an intervention’s objectives are pertinent to the needs, 
problems and issues to be addressed.
Scope — precise definition of the evaluation object, i.e. what is being evaluated.
Stakeholders — individuals, groups or organisations with an interest in the evaluated 
intervention or in the evaluation itself, particularly authorities that decided on and financed 
the intervention, managers, operators and spokespersons of the public concerned.
Steering group — the committee or group of stakeholders responsible for guiding the 
evaluation team.
Sustainability — the continuation of benefits from an intervention after major 
development assistance has been completed; the probability of continued long-term 
benefits.
Terms of reference — the terms of reference define the work and the schedule that must 
be carried out by the evaluation team. They recall the regulatory framework and specify the 
scope of an evaluation. They state the main motives for an evaluation and the questions 
asked. They sum up available knowledge and outline an evaluation method. They describe 
the distribution of the work and responsibilities among the people participating in an 
evaluation process. They fix the schedule and, if possible, the budget. They specify the 
qualifications required of candidate teams as well as the criteria to be used to select an 
evaluation team.
Tool — standardised procedure used to fulfil a function of evaluation (e.g. regression 
analysis or questionnaire survey). Evaluation tools serve to collect quantitative or 
qualitative data, synthesise judgement criteria, explain objectives, estimate impacts, and 
so on.
Validity — the extent to which the indicator accurately measures what is purports to 
measure.
Value for money — a value for money evaluation is a judgement as to whether the 
outcomes achieved are sufficient given the level of resources used to achieve them. It 
generally includes an assessment of the cost of running the programme, its efficiency (the 
outputs it achieves for its inputs) and its effectiveness (the extent to which it has achieved 
expected outcomes) and uses analytical approaches such as cost-effectiveness or cost–
benefit analyses.
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I Sources
The principal sources of the definitions contained in the glossary are listed below.
I  Bureau of Justice Assistance (no date), Guide to program evaluation (https://www.bja.
gov/evaluation/guide/bja-guide-program-evaluation.pdf). 
I  Cochrane Collaboration (no date), Glossary (http://community-archive.cochrane.org/
glossary).
I  European Commission (1999), Evaluating socio-economic programmes: glossary of 
300 concepts and technical terms, Office for Official Publications of the European 
Communities, Luxembourg.
I  European Commission (2000), Focus on results: strengthening evaluation of Commission 
activities, SEC (2000) 1051, European Commission, Brussels.
I  European Commission (2013), EVALSED: the resource for the evaluation of socio-
economic development, European Commission, Brussels. 
I  Farrington, D. P., Gottfredson, D. C., Sherman, L. W. and Welsh, B. C. (2002), ‘Maryland 
Scientific Methods Scale’, in Sherman, L. W., Farrington, D. P. et al. (editors), Evidence-
based crime prevention, pp. 13–21, Routledge, London.
I  Fretheim, A., Oxman, A. D., Lavis, J. N. and Lewin, S. (2009), ‘Support tools for evidence-
informed policymaking in health 18: Planning monitoring and evaluation of policies’, 
Health Research Policy and Systems 7, pp. 1–8.
I  OECD (2002), Glossary of key terms in evaluation and results based management, OECD 
Publications, Paris.
I  W. K. Kellogg Foundation (2004), Logic model development guide, W. K. Kellogg 
Foundation, Battle Creek.
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